LivaNova slides on study failure of depression treatment

Livanova

06/06/2024 15:08

** Shares of medical device maker LivaNova  LIVN.O  fall
~11.6% to $53.07
    ** Co says its vagus nerve stimulation (VNS) therapy did not
meet the main goal in a study testing it in patients with a
major depressive disorder called unipolar depression 
    ** VNS is a surgical procedure where a small device,
implanted in the body, is attached to the vagus nerve which
connects to areas in the brain believed to be involved in
regulating mood
    ** Co expects to publish study data in Q4 2024
    ** Including session's move, stock up 2.3% YTD

    

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))